Role of serum P1NP measurement for monitoring treatment response in osteoporosis

Biomarkers in Medicine

Volumn 2, Issue 5, 2008, Pages 495-508

  Samoszuk, Michael ^a   Leuther, Michael ^a   Hoyle, Nicholas ^a  

^a Roche Diagnostics Corporation   (United States)

Author keywords

Anabolic; Antiresorptive; Bisphosphorosis; Parathyroid hormone; PINP; Procollagen; Therapy monitoring; Turnover

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; CLODRONIC ACID; DEOXYPYRIDINOLINE; ESTRADIOL; IBANDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; PROCOLLAGEN; PYRIDINOLINE; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE; VITAMIN D; ZOLEDRONIC ACID;

BONE DENSITY; BONE FRAGILITY; BONE METABOLISM; BONE REMODELING; BONE TURNOVER; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DRUG WITHDRAWAL; HIGH RISK POPULATION; HORMONE INHIBITION; HUMAN; MONOTHERAPY; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PATIENT COMPLIANCE; PATIENT MONITORING; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VERTEBRA FRACTURE;

EID: 59949098895     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/17520363.2.5.495     Document Type: Review

References (39)

1. Sambrook P, Cooper C: Osteoporosis. Lancet 367, 2010-2018 (2006).
2. Department of Health and Human Services. Bone health and osteoporosis: a report of the Surgeon General. US Department of Health and Human Services, Office of the Surgeon General. Rockville, USA (2004).
3. Styrkarsdottir U, Halldorsson B, Gretarsdottir S et al.: Multiple genetic loci for bone mineral density and fractures. N. Engl. J. Med. 358, 2355-2365 (2008).
4. Vesper H, Cosman F, Endres D et al.: Application of biochemical markers of bone turnover in the assessment and monitoring of bone diseases; approved guideline. NCCLS24(22), 1-8 (2004).
5. Martin TJ, Sims NA: Osteociast-dèrived activity in the coupling of bone formation to resorption. Trends Mol. Med. 11 (2), 76-81 (2005).
6. Boyle WJ, Simonet WS, Lacey DL: Osteoclast differentiation and activation. Nature 423, 337-342 (2003).
7. Huybrechts KF, Ishak KJ, Caro JJ: Assessment of compliance with osteoporosis treatment and its consequences in a managed care. population. Bone 38, 922-928 (2006).
8. Tosteson AN, Grove MR, Hammond CS et al.: Early cliscontinuation of treatment for osteoporosis. Am. J. Med. 115 (3), 209-216 (2003).
9. Delmas PD, Brijens B, Eastell R et al.: Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 92(4), 1296-1304(2007).
10. Clowes JA, Peel NFA, Eastell R: The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J. Clin. Endocrinol. Metab. 89(3), 1117-1123 (2004).
11. Bonnick SL, Shulman L: Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am. J. Med. 119(4A), 25S-31S (2006).
12. Compston JE, Seeman E: Compliance with osteoporosis therapy is the weakest link. Lancet 368, 973-947 (2006).
13. Lekkerkerker F, Kanis A Alsayed N et al.: Adherence to treatment of osteoporosis: a need for study. Osteoporos. Int. 18, 1311-1317 (2007).
14. Garnero P, Vergnaud P, Hoyle N: Evaluation of a fully automated serum assay for total N-terminal propepticle of type I coliagen in postmenopausal osteoporosis. Clin. Chem. 54(1), 188-196 (2008).
15. Black DM, Greenspan SL, Ensrud KE et al.: The effects of PTH(1 -84) and dendronate, alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med. 349, 1207-1215 (2003).
16. Reginster JY, Sarkar S, Zegels B et al.: Reduction in P1NP, a marker of bone metabolismi with raloxifene treatment and its relationship with vertebral fracture risk. Bone 34, 344-351 (2004).
17. Sebba AI, Bonnick SL, Kagan R et al.: Response to therapy with once-week y alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis, Curr: Med Res. Opin. 20, 2031-2041 (2004).
18. Rosen CJ, Hochberg MC, Bonnick SL et al.: Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J. Bone Miner. Res. 20(1) 141-151 (2005).
19. Tahtela R, Seppanen J,. Laitinen K, Katajamaki A; Risteli J, Valimaki MJ: Serum tartrate-resistent acid phospha use 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopepticle of type I collagen and serum type I procollagen amino-terminal propetide. Osteoporos. Int. 16, 1109-1116 (2005).
20. Black DM, Bilezikian JF, Ensrud KE et al.: One year of alendronate aftei one year of PTH(1-84) for osteoporosis. N. Engl. J. Med. 353(6), 555-565 (2005).
21. Chen P, Satterwhite JH, Licata NA et al.: Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J. Bone Miner. Res. 20(6). 962-970 (2005).
22. Nenonen A, Cheng S, Ivaska KK et al.: Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markets of bone turnover. J Bone Miner. Res. 20(8), 1804-1812 (2005).
23. Deal C, Omizo M, Schwartz EN et al.: Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results form a 6-month double-blind placebo-controlled trial. J. Bone Miner. Res. 21(11). 1905-1911 (2005).
24. McClung MR, San Martin J. Miller PD et al.: Opposite bone remodeling effects of teriparaiide and atendronate in increasing bone mass. Arch. Intern. Med. 165. 1762-1768 (2005).
25. Eastell R, Krege JH, Chen Peiqu, Glass EV, Reginster J-Y: Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr. Med. Res. Opin. 22(1), 61-66 (2006).
26. Krege JH, Blumsohn A, Nickelsen TA, Marin F, Chen P, Eastell R: Testing an algorithm for using PINP to monitor treatment of patients with teriparatide. J. Bone Miner. Res. 21 (Suppl. 1), S302 (2006).
27. Middleton FT, Steel SA, Doherty SM: The effect of prior bisphosphonate exposure On the treatment response to teriparatide in clinical practice. Calcif. Tizue Int. 81, 335-340 (2007).
28. Anastasilakis AD, Goulis DG, Polyzos SA et al.: Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomized trial. Int. J. Clin. Tract. 1768, 1-6 (2008).
29. Miller PD: Monitoring osteoporosis therapies. Curr. Osteoporos. Rep. 5(1), 38-43 (2007).
30. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA. Pak CY: Severely suppressed hone turnover: a potential complication of alendronate therapy. J. Clin. Endocrinol. Metab. 90, 1294-1301 (2005).
31. Armamento-Villareal R, Panwar V. Novack D: Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N. Engl. J. Med. 355(19), 2048-2050 (2006).
32. Schneider JP: Should bisphosphonates be continued Indefinitely? An unusual fracture in a healthy woman on long-term alendronate. Geriatriacs 31-33 (2006).
33. Goh SK, Yang KY, Koh JS et al.: Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J. Bone Joint Surg. Br. 89, 349-353 (2007).
34. Imai K, Yamamoto S, Anamizu Y, Horiuchi T, Pelvic insufficiency fracture associated with severe suppression of bone turnover by alendronate therapy. J. Bone Miner. Metab. 25, 333-336 (2007).
35. Cheung RKH, Leung KK, Lee KC, Chow TC: Sequential non-traumatic femoral shaft fractures in a patient on long-term alendronate. Hong Kong Med. J. 13, 485-489 (2007).
36. Lenart BA, Lorich DG, Lane JM: Atypical fractures of the femoral diaphysis In postmenopausal women taking alendronate. N. Engl. J. Med. 358, 1304-1306 (2008).
37. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F. Lorich DG: Low-energy femoral shaft fractures associated with alendronate use. J. Orthop. Trauma. 22(5), 346-350 (2008).
38. Kwek EBK, Goh SK, Koh JSB, Png MA, Howe TS: An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury Int. J. Care Injured 39, 224-231 (2008).
39. Visekruna M, Wilson D, McKiernan FE: Severely suppressed bone turnover and atypical skeletal fragility. J. Clin. Endocrinol. Metab. 93(8), 2948-2952 (2008).